Data Sharing & Reproducibility Policy

JPDMHD encourages and, for clinical research, requires transparency in reporting and data availability to support the reproducibility of published findings.

Data Availability Statement

All manuscripts must include a 'Data Availability Statement' before the References section. This statement must describe whether the underlying data are available and, if so, where and how they can be accessed. Acceptable statements include:

• 'The datasets generated and analysed during the current study are available in [repository name] at [URL/DOI].'
• 'The data that support the findings of this study are available from the corresponding author upon reasonable request.'
• 'All data generated or analysed during this study are included in this published article (and its supplementary information files).'
• 'The datasets generated during the current study are not publicly available due to [reason, e.g., patient confidentiality] but are available from the corresponding author on reasonable request.'

Clinical Trials

Authors reporting clinical trials are required to register the trial in a publicly accessible registry (e.g., ClinicalTrials.gov, ISRCTN, WHO ICTRP) before enrolment begins and to report the registry name and trial registration number in the manuscript. JPDMHD follows the ICMJE guidelines on clinical trial registration.

Reporting Guidelines

Authors are encouraged to use relevant reporting guidelines for their study design. Examples include CONSORT (randomised controlled trials), STROBE (observational studies), PRISMA (systematic reviews), and CARE (case reports). Completed checklists should be submitted as supplementary material.

Data Retention

Authors are expected to retain raw data for a minimum of 10 years after publication and to provide access to these data to editors or reviewers upon request during that period, subject to ethical constraints.